Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is one of the stocks on Jim Cramer’s radar recently. When Cramer was asked about the ...
Detailed price information for Silence Therapeutics Plc ADR (SLN-Q) from The Globe and Mail including charting and trades.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue ...
Incyte on Tuesday raised its annual sales forecast for Jakafi after the cancer drug helped the company post third-quarter results above Wall Street estimates.
Barchart on MSN
1 Growth Stock Under $100 to Buy Before It Soars
Incyte (INCY) reported a breakout quarter on Oct. 28, beating Wall Street’s revenue and earnings estimates. Best known for ...
TipRanks on MSN
Silence Therapeutics completes patient enrollment in SANRECO
Silence Therapeutics (SLN) announced it has completed patient enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA ...
Disc Medicine is planning to launch a trial by year's end to test DISC-3405, its treatment candidate for iron overload, in ...
NORRIDGEWOCK – After a hard-fought and painful battle with Polycythemia Vera, a rare bone marrow disease, Craig Lee Judd passed on … NORRIDGEWOCK – After a hard-fought and painful battle with ...
A doer, motivator, creator and adventurer, Meredith will be best remembered as upbeat, outspoken and confident, with a remarkable drive to excel at anything she did.
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈